{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:11:29Z","timestamp":1778749889885,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"publisher","award":["HR20C0025"],"award-info":[{"award-number":["HR20C0025"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"publisher","award":["HI21C1137"],"award-info":[{"award-number":["HI21C1137"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.prp.2024.155806","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T03:02:45Z","timestamp":1735614165000},"page":"155806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Clinicopathologic and genomic characteristics of biliary tract carcinomas with TERT promoter mutations among East Asian population"],"prefix":"10.1016","volume":"266","author":[{"given":"Inwoo","family":"Hwang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So Young","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deok Geun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kee\u2011Taek","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1162-9205","authenticated-orcid":false,"given":"Kyoung-Mee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2024.155806_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/carcin\/bgp268","article-title":"Telomeres and telomerase in cancer","volume":"31","author":"Artandi","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.prp.2024.155806_bib2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/13495","article-title":"Inhibition of telomerase limits the growth of human cancer cells","volume":"5","author":"Hahn","year":"1999","journal-title":"Nat. Med"},{"key":"10.1016\/j.prp.2024.155806_bib3","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","article-title":"TERT promoter mutations in familial and sporadic melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.prp.2024.155806_bib4","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent TERT promoter mutations in human melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.prp.2024.155806_bib5","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/ncomms3185","article-title":"Frequency of TERT promoter mutations in human cancers","volume":"4","author":"Vinagre","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2024.155806_bib6","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1073\/pnas.1303607110","article-title":"TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal","volume":"110","author":"Killela","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.prp.2024.155806_bib7","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1038\/ncomms3218","article-title":"High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions","volume":"4","author":"Nault","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2024.155806_bib8","doi-asserted-by":"crossref","first-page":"17426","DOI":"10.1073\/pnas.1310522110","article-title":"TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism","volume":"110","author":"Rachakonda","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.prp.2024.155806_bib9","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1038\/ncomms4401","article-title":"Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma","volume":"5","author":"Heidenreich","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2024.155806_bib10","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/21655979.2021.1915725","article-title":"The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer","volume":"12","author":"Wan","year":"2021","journal-title":"Bioengineered"},{"key":"10.1016\/j.prp.2024.155806_bib11","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1530\/ERC-16-0219","article-title":"TERT promoter mutations and long-term survival in patients with thyroid cancer","volume":"23","author":"Kim","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.prp.2024.155806_bib12","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00401-018-1913-0","article-title":"cIMPACT-NOW update 3: recommended diagnostic criteria for \"Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV\"","volume":"136","author":"Brat","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.prp.2024.155806_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/oncolo\/oyad208","article-title":"TERT promoter mutations frequency across race, sex, and cancer type","volume":"29","author":"El Zarif","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.prp.2024.155806_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002127","article-title":"TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor","volume":"9","author":"de Kouchkovsky","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2024.155806_bib15","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/ng.3126","article-title":"Trans-ancestry mutational landscape of hepatocellular carcinoma genomes","volume":"46","author":"Totoki","year":"2014","journal-title":"Nat. Genet"},{"key":"10.1016\/j.prp.2024.155806_bib16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3748\/wjg.v21.i1.311","article-title":"M. Ozturk, Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations","volume":"21","author":"Cevik","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.prp.2024.155806_bib17","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.ejca.2015.03.010","article-title":"Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation","volume":"51","author":"Huang","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.prp.2024.155806_bib18","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.celrep.2017.06.008","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles","volume":"19","author":"Farshidfar","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.prp.2024.155806_bib19","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1038\/ncomms7120","article-title":"Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity","volume":"6","author":"Fujimoto","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2024.155806_bib20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/path.5243","article-title":"Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma","volume":"248","author":"Joseph","year":"2019","journal-title":"J. Pathol."},{"key":"10.1016\/j.prp.2024.155806_bib21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/his.13084","article-title":"Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance","volume":"70","author":"Sasaki","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2024.155806_bib22","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic determinants of outcome in intrahepatic cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.prp.2024.155806_bib23","doi-asserted-by":"crossref","first-page":"615","DOI":"10.21037\/hbsn.2019.08.05","article-title":"Comprehensive molecular profiling of extrahepatic cholangiocarcinoma in Chinese population and potential targets for clinical practice","volume":"8","author":"Xue","year":"2019","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"4","key":"10.1016\/j.prp.2024.155806_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/PO.18.00414","article-title":"Intrahepatic cholangiocarcinoma: genomic heterogeneity between eastern and western patients","author":"Cao","year":"2020","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.prp.2024.155806_bib25","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00428-014-1658-7","article-title":"Frequency of TERT promoter mutations in primary tumors of the liver","volume":"465","author":"Quaas","year":"2014","journal-title":"Virchows Arch."},{"key":"10.1016\/j.prp.2024.155806_bib26","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2023.2223375","article-title":"Genomic profiling, prognosis, and potential interventional targets in young and old patients with cholangiocarcinoma","volume":"24","author":"Wang","year":"2023","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.prp.2024.155806_bib27","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2024.155806_bib28","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.21037\/jgo-21-776","article-title":"Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma","volume":"12","author":"Zheng","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.prp.2024.155806_bib29","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/ijc.28633","article-title":"Low frequency of TERT promoter mutations in a large cohort of gallbladder and gastric cancers","volume":"134","author":"Qu","year":"2014","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.prp.2024.155806_bib30","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1158\/1078-0432.CCR-22-1954","article-title":"Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention","volume":"28","author":"Giraldo","year":"2022","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.prp.2024.155806_bib31","article-title":"Comparative analysis of microsatellite instability by next-generation sequencing, MSI PCR and MMR immunohistochemistry in 1942 solid cancers","volume":"233","author":"Kang","year":"2022","journal-title":"Pathol. Res Pr."},{"key":"10.1016\/j.prp.2024.155806_bib32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.prp.2024.155806_bib33","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/modpathol.2011.68","article-title":"Squamous cell and adenosquamous carcinomas of the gallbladder: clinicopathological analysis of 34 cases identified in 606 carcinomas","volume":"24","author":"Roa","year":"2011","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2024.155806_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.621594","article-title":"Treatment and survival patterns of primary adenosquamous carcinoma of the liver: a retrospective analysis","volume":"11","author":"Gou","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.prp.2024.155806_bib35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000511919","article-title":"ERBB2 pathway in biliary tract carcinoma: clinical implications of a targetable pathway","volume":"44","author":"Jacobi","year":"2021","journal-title":"Oncol. Res Treat."},{"key":"10.1016\/j.prp.2024.155806_bib36","article-title":"HER2 aberrations as a novel marker in advanced biliary tract cancer","volume":"12","author":"Kim","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.prp.2024.155806_bib37","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2024.155806_bib38","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4006","article-title":"Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): an investigator-initiated multicenter phase 2 study (HERB trial)","volume":"40","author":"Ohba","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2024.155806_bib39","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2024.155806_bib40","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"H.-B.-s. group, Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2024.155806_bib41","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19\u201314)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.prp.2024.155806_bib42","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.23.01193","article-title":"Trastuzumab plus gemcitabine-cisplatin for treatment-naive human epidermal growth factor receptor 2-positive biliary tract adenocarcinoma: a multicenter, open-label, phase II study (TAB)","volume":"42","author":"Ostwal","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2024.155806_bib43","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1002\/cam4.3376","article-title":"TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment","volume":"9","author":"Li","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.prp.2024.155806_bib44","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s12072-022-10419-3","article-title":"Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma","volume":"16","author":"Zhao","year":"2022","journal-title":"Hepatol. Int"},{"key":"10.1016\/j.prp.2024.155806_bib45","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/hep.32135","article-title":"Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas","volume":"75","author":"An","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.prp.2024.155806_bib46","first-page":"8","article-title":"Telomerase reverse transcriptase promoter mutations in hepatocellular carcinogenesis","volume":"5","author":"Zi-Xian","year":"2019","journal-title":"Hepatoma Res."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824007179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824007179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:28:16Z","timestamp":1778747296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033824007179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":46,"alternative-id":["S0344033824007179"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2024.155806","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathologic and genomic characteristics of biliary tract carcinomas with TERT promoter mutations among East Asian population","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2024.155806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"155806"}}